Compare G & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | G | GRFS |
|---|---|---|
| Founded | 1997 | 1940 |
| Country | Bermuda | Spain |
| Employees | 140000 | 25247 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.5B |
| IPO Year | 2007 | N/A |
| Metric | G | GRFS |
|---|---|---|
| Price | $34.21 | $8.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $49.50 | $10.15 |
| AVG Volume (30 Days) | ★ 2.5M | 573.0K |
| Earning Date | 05-07-2026 | 07-28-2022 |
| Dividend Yield | ★ 2.21% | 1.80% |
| EPS Growth | ★ 9.82 | N/A |
| EPS | ★ 3.13 | N/A |
| Revenue | ★ $2,279,438,000.00 | N/A |
| Revenue This Year | $9.20 | $4.49 |
| Revenue Next Year | $7.27 | $6.42 |
| P/E Ratio | ★ $10.99 | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.14 | $7.08 |
| 52 Week High | $50.24 | $11.14 |
| Indicator | G | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 50.20 |
| Support Level | N/A | $7.64 |
| Resistance Level | $38.03 | $8.88 |
| Average True Range (ATR) | 1.08 | 0.19 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 22.05 | 39.06 |
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.